New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAs compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cance
Oncology January 04,2024
Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAs compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cance
Oncology January 04,2024
The origin-of-life molecule, a key to cancer research

The origin-of-life molecule, a key to cancer research

byUniversity of SevilleSchematic model of the regulation and role of RNAPII-generated nascent RNA to guide DNA end resection and DSB repair by HR. Credit:Nature Communications(2022).
Oncology January 04,2024
The origin-of-life molecule, a key to cancer research

The origin-of-life molecule, a key to cancer research

byUniversity of SevilleSchematic model of the regulation and role of RNAPII-generated nascent RNA to guide DNA end resection and DSB repair by HR. Credit:Nature Communications(2022).
Oncology January 04,2024
Oncology therapy at the end-of-life: Have we missed the mark?

Oncology therapy at the end-of-life: Have we missed the mark?

by Yale Cancer CenterCredit:JAMA Oncology(2022). DOI: 10.1001/jamaoncol.2022.4666Continued treatment for patients with cancer near end-of-life delays conversations about goals of care and
Oncology January 04,2024
Oncology therapy at the end-of-life: Have we missed the mark?

Oncology therapy at the end-of-life: Have we missed the mark?

by Yale Cancer CenterCredit:JAMA Oncology(2022). DOI: 10.1001/jamaoncol.2022.4666Continued treatment for patients with cancer near end-of-life delays conversations about goals of care and
Oncology January 04,2024
Does living along the US-Mexico border affect the chances of survival among children with leukemia?

Does living along the US-Mexico border affect the chances of survival among children with leukemia?

byWileyCredit: Unsplash/CC0 Public DomainResiding in border regions was linked with a higher risk of dying within five years among children with acute lymphoblastic leukemia, the most common typ
Oncology January 04,2024
Does living along the US-Mexico border affect the chances of survival among children with leukemia?

Does living along the US-Mexico border affect the chances of survival among children with leukemia?

byWileyCredit: Unsplash/CC0 Public DomainResiding in border regions was linked with a higher risk of dying within five years among children with acute lymphoblastic leukemia, the most common typ
Oncology January 04,2024
Biochemists, cancer biologists find key vulnerability in rare brain tumors

Biochemists, cancer biologists find key vulnerability in rare brain tumors

by Anne Manning,Colorado State UniversityCredit: Pixabay/CC0 Public DomainSince the start of her career, Jennifer DeLuca has been fascinated by mitosis, the everyday biological process of cell d
Oncology January 04,2024
Biochemists, cancer biologists find key vulnerability in rare brain tumors

Biochemists, cancer biologists find key vulnerability in rare brain tumors

by Anne Manning,Colorado State UniversityCredit: Pixabay/CC0 Public DomainSince the start of her career, Jennifer DeLuca has been fascinated by mitosis, the everyday biological process of cell d
Oncology January 04,2024
Renal impairment linked to worse prognosis in IgD multiple myeloma

Renal impairment linked to worse prognosis in IgD multiple myeloma

by Elana GotkineFor patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no
Oncology January 04,2024
Renal impairment linked to worse prognosis in IgD multiple myeloma

Renal impairment linked to worse prognosis in IgD multiple myeloma

by Elana GotkineFor patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no
Oncology January 04,2024
First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

by ECOG-ACRIN Cancer Research GroupCredit: Pixabay/CC0 Public DomainThe ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of
Oncology January 04,2024
First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

by ECOG-ACRIN Cancer Research GroupCredit: Pixabay/CC0 Public DomainThe ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of
Oncology January 04,2024
Neuronal molecule makes prostate cancer more aggressive

Neuronal molecule makes prostate cancer more aggressive

byThomas Jefferson UniversityCredit: Unsplash/CC0 Public DomainProstate cancer is the second most common cancer and the second leading cause of cancer death among American men. Now, researchers
Oncology January 04,2024
Neuronal molecule makes prostate cancer more aggressive

Neuronal molecule makes prostate cancer more aggressive

byThomas Jefferson UniversityCredit: Unsplash/CC0 Public DomainProstate cancer is the second most common cancer and the second leading cause of cancer death among American men. Now, researchers
Oncology January 04,2024
Altered cell behavior behind resistance in neuroblastoma

Altered cell behavior behind resistance in neuroblastoma

byLund UniversityEstablishment and application of a COJEC-like treatment protocol using NB PDX models.(A) Schematic representation of the experimental design. Mice were injected subcutaneously (
Oncology January 04,2024
Altered cell behavior behind resistance in neuroblastoma

Altered cell behavior behind resistance in neuroblastoma

byLund UniversityEstablishment and application of a COJEC-like treatment protocol using NB PDX models.(A) Schematic representation of the experimental design. Mice were injected subcutaneously (
Oncology January 04,2024
Origins of glioma brain cancer found to be in the epigenome

Origins of glioma brain cancer found to be in the epigenome

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainWhile cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at D
Oncology January 04,2024
Origins of glioma brain cancer found to be in the epigenome

Origins of glioma brain cancer found to be in the epigenome

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainWhile cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at D
Oncology January 04,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com